Skip to main content

Day: August 27, 2025

Intra-Group Merger Finalised

On 11 July 2025, Bigbank AS announced via a stock exchange notice the conclusion of intra-group merger agreement between Balti Võlgade Sissenõudmise Keskus OÜ (the company being acquired), a subsidiary of Bigbank AS, and OÜ Rüütli Property (the acquiring company), a subsidiary of OÜ Rüütli Majad which is a subsidiary of Bigbank AS.  Bigbank AS hereby announces that the merger was officially recorded in the Estonian commercial register on 26 August 2025. As a result, Balti Võlgade Sissenõudmise Keskus OÜ has been deleted from the commercial register as of 26 August 2025.  Bigbank AS (www.bigbank.eu), with over 30 years of operating history, is a commercial bank owned by Estonian capital. As of 31 July 2025, the bank’s total assets amounted to 3.1 billion euros, with equity of 284 million euros. Operating in nine countries, the bank...

Continue reading

Immuron partners with InvestorHub

MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company’s commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub – bringing content and communication into a single integrated platform. The Company will also be regularly uploading new content via the hub, including videos accompanying select announcements, educational material, interviews and corporate research. Chief Executive Officer, Steven Lydeamore, commented: “With a number of near term milestones coming up, there has...

Continue reading

Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

SHANGHAI, Aug. 26, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2025 interim financial results and provided corporate updates. FINANCIAL HIGHLIGHTSAs of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representing an increase of approximately 49% compared to 2024, driven mainly by pharmaceutical sales. In particular, the domestic sales revenue of our core product, TUOYI® (toripalimab), reached approximately RMB954 million, an increase of approximately 42% from 2024. Total research and development (“R&D”) expenses of the company were approximately...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.